NCT03193437View on ClinicalTrials.gov

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

July 27, 2020

Study Completion Date

January 31, 2022

Conditions
ThymomaAdvanced Thymic Epithelial Tumor
Interventions
DRUG

Open Label Selinexor

Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.

Trial Locations (2)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

07601

John Theurer Cancer Center - Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
collaborator

Hackensack Meridian Health

OTHER

collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Georgetown University

OTHER

NCT03193437 - Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy | Biotech Hunter | Biotech Hunter